10601-98-6Relevant articles and documents
Ionic-liquid-supported organocatalyst for the enantioselective Michael addition of ketones to nitroolefins
Wu, Lu-Yong,Yan, Ze-Yi,Xie, Yong-Xin,Niu, Yan-Ning,Liang, Yong-Min
, p. 2086 - 2090 (2007)
Ionic-liquid-supported triazole-pyrrolidine 2, for the direct asymmetric Michael reaction was successfully synthesized. The supported catalyst demonstrated good activity and high enantioselectivity in the addition of cyclohexanone to nitroolefins. Further
Sensor with a scaffold having changeable conformations
-
Page/Page column 19; 20; 27, (2017/09/26)
The present invention relates to a scaffolded sensor with a container comprising a drug for triggering drug release, wherein the scaffold is intrinsically conformationally metastable and a method to its manufacture.
N-[2-methyl-5-(triazol-1-yl)phenyl]pyrimidin-2-amine as a Scaffold for the synthesis of inhibitors of Bcr-Abl
Arioli, Federica,Borrelli, Stella,Colombo, Francesco,Falchi, Federico,Filippi, Irene,Crespan, Emmanuele,Naldini, Antonella,Scalia, Giusy,Silvani, Alessandra,Maga, Giovanni,Carraro, Fabio,Botta, Maurizio,Passarella, Daniele
experimental part, p. 2009 - 2018 (2012/06/30)
N-[2-Methyl-5-(triazol-1-yl)phenyl]pyrimidin-2-amine derivatives were synthesized and evaluated invitro for their potential use as inhibitors of Bcr-Abl. The design is based on the bioisosterism between the 1,2,3-triazole ring and the amide group. The synthesis involves a copper(I)-catalyzed azide-alkyne cycloaddition (CuAAC) as the key step, with the exclusive production of anti-(1,4)-triazole derivatives. One of the compounds obtained shows general activity similar to that of imatinib; in particular, it was observed to be more effective in decreasing the fundamental function of cdc25A phosphatases in the K-562 cell line. Willing and Abl inhibitors! N-[2-Methyl-5-(triazol-1-yl)phenyl]pyrimidin-2-amine derivatives were synthesized by a copper(I)-catalyzed azide-alkyne cycloaddition (CuAAC) as a key step, with anti-(1,4)-triazole derivatives as the exclusive products. One of these compounds shows general activity similar to that of imatinib, and in particular, it is more effective in decreasing the fundamental function of cdc25A phosphatases in the K-562 cell line.